Pipeline
Original products
| Products | Clinical indication | Region |  |
Licensee | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Ripasudil hydrochloride hydrate | GLANATEC® | Glaucoma and ocular hypertension | Japan | Kowa | |||||||
| Asia | |||||||||||
| Vietnam | |||||||||||
| K-321 | Fuchs endothelial corneal dystrophy | U.S. | |||||||||
| K-232 (Ripasudil hydrochloride hydrate/ Brimonidine tartrate) | K-232 | Glaucoma and ocular hypertension | Japan | ||||||||
| H-1337 | Glaucoma and ocular hypertension | U.S. | Developed internally | ||||||||
In-licensed products
| Products | Clinical indication | Region | |
Licensee | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| DW-1001 | Ophthalmic treatment agent | Japan | ROHTO Pharmaceutical | |||||||
| DW-1002 | ILM peeling | Europe, US and Canada | DORC | |||||||
| ILM staining | Japan | Wakamoto Pharmaceutical | ||||||||
| Cataract surgery | Japan | Wakamoto Pharmaceutical | ||||||||
| DW-5LBT | Neuropathic pain after shingles | US | Jointly developed with MEDRx | |||||||
R&D Projects for new drug discovery
| Products | Clinical indication | Development process | Partner |
|---|---|---|---|
| Signal transduction inhibitor developing projects | Ophthalmology,Central Nervous System,Cardiovascular System,Respiratory System | Fundamental Research | Mie Univ. etc. |
| New device developing projects | Glaucoma,Corneal disorders,Retinal diseases | Fundamental Research | Glaukos |
Pipeline developed by subsidiary JIT
| Products | Clinical indication | Region | Development process | Partner (Origin) |
|---|---|---|---|---|
| Treatment for retinopathy of prematurity |
Retinopathy of prematurity | Japan | Non-clinical studies | JIT(Tokyo University of Agriculture and Technology) |